Novocure Q2 FY26 net loss narrows to USD 15.66 million; revenue rises 16% to USD 183.58 million - NVCR News | RalliesNovocure Q2 FY26 net loss narrows to USD 15.66 million; revenue rises 16% to USD 183.58 million
N
NVCR• Second-quarter results
- Novocure posted Q2 net revenues up 16% year over year to USD 183.6 million, while net loss narrowed to USD 15.7 million.
- Gross margin widened 4 percentage points to 78%, helped by a USD 4.9 million tariff refund and lower array costs.
- Operating loss narrowed to USD 10.6 million, while financial results swung to a USD 1.9 million net expense on lower interest income.
- Non-GAAP adjusted EBITDA turned positive at USD 10.8 million from a loss a year earlier.
Patient growth and Optune Pax uptake
- Active patients rose 18% globally to 5,128, including 285 on Optune Pax in the U.S. following its FDA approval in the first quarter.
•
